Respiratory Diseases Drugs Global Market Report 2018

Starting Price : $ 4000.00 | Pages : 125 | Published : February 2018 | SKU CODE : 3261 | Format :

Respiratory Diseases Drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, codral®, coldrex® and lemsip®.

North America was the largest region in the respiratory diseases drugs market in 2017, accounting for 48% market share. This was mainly due to high number of patients with respiratory diseases, more people covered under medical insurance programs and higher pricing of medications in the USA. Asia Pacific was the second largest region accounting for 19% market share. Africa was the smallest region accounting for 2% market share. This is attributed to the small size of population in the region.

The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.

The companies covered are GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, and Johnson & Johnson.

The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.

The respiratory diseases drugs market is segmented into Anti-Asthmatics And COPD Drugs; and Cough And Cold Preparations.

Anti-Asthmatics And COPD Drug companies produce drugs that can be used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

Cough And Cold Preparations Drug companies produce drugs containing active ingredients such as acetaminophen, antihistamines, dextromethorphan, decongestants, and ethanol that can be used to treat cough and cold.

Next-gen Biologics- The Way Forward

The Telemedicine Technology Market Will More Than Double by 2022

Minor Orthopedic Replacement Implants Global Market Exceeds $1.5 Billion

Minor orthopedic implant market to be worth $2.2 billion by 2021, analysts say

Organs-on-Chips to Revolutionize the Drug Development Industry

Russia’s Musculoskeletal Drugs Market Is Catching Up With The Rest Of Europe

The Fastest Growing Regions for Dermatological Drug Sales Are the Middle East and South America

Growth of Middle Class Is Causing Heart Drugs Market In Asia Pacific To Accelerate, Says TBRC

Blood Glucose Test Strips Global Market Report 2018

View Report

Veterinary Services Global Market Report 2018

View Report

Podiatry Services Global Market Strategies and Opportunities to 2021

View Report

Minor Orthopedic Implants Replacement Global Market Opportunities And Strategies To 2021

View Report

Biologics Global Market Opportunities And Strategies To 2021

View Report

Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021

View Report

Blood Glucose Test Strips Global Market Opportunities And Strategies To 2021

View Report

Veterinary Serices Global Market Opportunities And Strategies To 2021

View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)